Hormone Therapy News

ORLANDO Fla. — In this video perspective, Michelle Forcier, MD, MPH, professor of pediatrics and assistant dean of medicine at The Warren Alpert Medical School of Brown University, discusses the AAP’s recent policy statement supporting the need for “gender-affirming care” for youth.

Here’s a look at the most popular recent hormone therapy reports at Endocrine Today. Readers were interested in cardiometabolic risks of hormonal contraception as well as FDA approvals for testosterone self-injections and bioidentical hormone therapies for menopausal hot flashes.

A new risk prediction score for polycystic ovary syndrome suggests that four clinical variables may best predict the condition in women, including free androgen index, anti-Müllerian hormone levels, waist circumference and 17-hydroxyprogesterone levels, according to findings published in Clinical Endocrinology.

Patients with growth hormone deficiency due to nonfunctioning pituitary adenoma experienced excessive morbidity due to cerebral infarction and sepsis regardless of whether they received long-term GH therapy, whereas treatment was associated with a normal incidence of type 2 diabetes, despite higher BMI and more severe hypopituitarism in treated patients, according to findings from an observational, registry-based study.

An analysis of 12 years of real-world patient data suggests that the growth hormone blocker pegvisomant is a safe and effective treatment for acromegaly, with a low occurrence of pituitary tumor enlargement and no reports of treatment-related liver failure, according to findings published in the European Journal of Endocrinology.

The FDA has approved the first bioidentical hormone therapy combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause, TherapeuticsMD announced in a press release.

BOSTON — Among the increasing numbers of U.S. women with metabolic syndrome, choice of contraceptive method can influence their risk for cardiovascular disease, according to a presenter at the Cardiometabolic Health Congress.

Prepubertal children with short stature who achieved catch-up height with growth hormone therapy were able to maintain normal height velocity after a reduction in GH dose, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

The FDA on Monday approved Antares Pharma’s testosterone enanthate injection Xyosted for testosterone replacement therapy in men with primary hypogonadism or hypogonadotropic hypogonadism, the company announced in a press release.

Exposure to bisphenol A, or BPA, at a dose deemed safe by U.S. regulatory agencies may change human glucose-stimulated insulin response, according to findings published in the Journal of the Endocrine Society.